Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Investing in public health-driving prosperity for the present and future generations.

Dyakova M, Hamelmann C.

Eur J Public Health. 2018 Jun 1;28(3):393-394. doi: 10.1093/eurpub/ckx228. No abstract available.

PMID:
29790992
2.

Key policies for addressing the social determinants of health and health inequities [Internet].

Saunders M, Barr B, McHale P, Hamelmann C.

Copenhagen: WHO Regional Office for Europe; 2017.

3.
4.

Kazakhstan can achieve ambitious HIV targets despite expected donor withdrawal by combining improved ART procurement mechanisms with allocative and implementation efficiencies.

Shattock AJ, Benedikt C, Bokazhanova A, Đurić P, Petrenko I, Ganina L, Kelly SL, Stuart RM, Kerr CC, Vinichenko T, Zhang S, Hamelmann C, Manova M, Masaki E, Wilson DP, Gray RT.

PLoS One. 2017 Feb 16;12(2):e0169530. doi: 10.1371/journal.pone.0169530. eCollection 2017.

5.

The effectiveness of community based distribution of injectable contraceptives using community health extension workers in Gombe State, Northern Nigeria.

Abdul-Hadi RA, Abass MM, Aiyenigba BO, Oseni LO, Odafe S, Chabikuli ON, Ibrahim MD, Hamelmann C, Ladipo OA.

Afr J Reprod Health. 2013 Jun;17(2):80-8.

PMID:
24069754
6.

Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.

Eluwa GI, Badru T, Agu KA, Akpoigbe KJ, Chabikuli O, Hamelmann C.

BMC Clin Pharmacol. 2012 Feb 27;12:7. doi: 10.1186/1472-6904-12-7. Erratum in: BMC Clin Pharmacol. 2012;12:14. Agu, Kenneth A [added]; Chabikuli, Otto [added]; Hamelmann, Christoph [added].

7.

HIV prevalence and risk behaviours among men having sex with men in Nigeria.

Merrigan M, Azeez A, Afolabi B, Chabikuli ON, Onyekwena O, Eluwa G, Aiyenigba B, Kawu I, Ogungbemi K, Hamelmann C.

Sex Transm Infect. 2011 Feb;87(1):65-70. doi: 10.1136/sti.2008.034991. Epub 2010 Sep 6.

PMID:
20820061
8.

Integrating reproductive health and HIV indicators into the Nigerian health system--building an evidence base for action.

Chukwujekwu O, Chabikuli NO, Merrigan M, Awi D, Hamelmann C.

Afr J Reprod Health. 2010 Mar;14(1):109-16.

PMID:
20695143
9.

The use of routine monitoring and evaluation systems to assess a referral model of family planning and HIV service integration in Nigeria.

Chabikuli NO, Awi DD, Chukwujekwu O, Abubakar Z, Gwarzo U, Ibrahim M, Merrigan M, Hamelmann C.

AIDS. 2009 Nov;23 Suppl 1:S97-S103. doi: 10.1097/01.aids.0000363782.50580.d8.

PMID:
20081394
10.

Human genetic resistance to Onchocerca volvulus: evidence for linkage to chromosome 2p from an autosome-wide scan.

Timmann C, van der Kamp E, Kleensang A, König IR, Thye T, Büttner DW, Hamelmann C, Marfo Y, Vens M, Brattig N, Ziegler A, Horstmann RD.

J Infect Dis. 2008 Aug 1;198(3):427-33. doi: 10.1086/589720.

PMID:
18558870
11.

Cutaneous pathology in onchocerciasis associated with pronounced systemic T-helper 2-type responses to Onchocerca volvulus.

Timmann C, Abraha RS, Hamelmann C, Buttner DW, Lepping B, Marfo Y, Brattig N, Horstmann RD.

Br J Dermatol. 2003 Oct;149(4):782-7.

PMID:
14616370
12.
13.

Pattern of connexin 26 (GJB2) mutations causing sensorineural hearing impairment in Ghana.

Hamelmann C, Amedofu GK, Albrecht K, Muntau B, Gelhaus A, Brobby GW, Horstmann RD.

Hum Mutat. 2001;18(1):84-5.

PMID:
11439000
14.

Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis.

Hoerauf A, Volkmann L, Hamelmann C, Adjei O, Autenrieth IB, Fleischer B, Büttner DW.

Lancet. 2000 Apr 8;355(9211):1242-3.

PMID:
10770311
15.

Malariometric update for the rainforest and savanna of Ashanti region, Ghana.

Browne EN, Frimpong E, Sievertsen J, Hagen J, Hamelmann C, Dietz K, Horstmann RD, Burchard GD.

Ann Trop Med Parasitol. 2000 Jan;94(1):15-22.

PMID:
10723520
16.

STD services for women at truck stop in Tanzania: evaluation of acceptable approaches.

Nyamuryekung'e K, Laukamm-Josten U, Vuylsteke B, Mbuya C, Hamelmann C, Outwater A, Steen R, Ocheng D, Msauka A, Dallabetta G.

East Afr Med J. 1997 Jun;74(6):343-7.

PMID:
9487393
17.

Putative serine/threonine protein kinase expressed in complement-resistant forms of Entamoeba histolytica.

Urban B, Blasig C, Förster B, Hamelmann C, Horstmann RD.

Mol Biochem Parasitol. 1996 Oct 1;80(2):171-8.

PMID:
8892294
18.

Improved method for the concentration and purification of faecal cysts of Entamoeba histolytica for use as antigen.

Jyothi R, Foerster B, Hamelmann C, Shetty NP.

J Trop Med Hyg. 1993 Aug;96(4):249-50.

PMID:
8345546
19.

Complement resistance of pathogenic Entamoeba histolytica mediated by trypsin-sensitive surface component(s).

Hamelmann C, Urban B, Foerster B, Horstmann RD.

Infect Immun. 1993 May;61(5):1636-40.

20.

Induction of complement resistance in cloned pathogenic Entamoeba histolytica.

Hamelmann C, Foerster B, Burchard GD, Shetty N, Horstmann RD.

Parasite Immunol. 1993 Apr;15(4):223-8.

PMID:
8506118
21.

Lysis of pathogenic and nonpathogenic Entamoeba histolytica by human complement: methodological analysis.

Hamelmann C, Foerster B, Burchard GD, Horstmann RD.

Parasite Immunol. 1992 Jan;14(1):23-35.

PMID:
1557228

Supplemental Content

Loading ...
Support Center